Pancreatic β-Cell Function in Diabetes Pathophysiology

Pancreatic β-cells, residing within the islets of Langerhans, are the sole physiological source of insulin, the hormone that lowers blood glucose by promoting cellular uptake and metabolic storage. In type 1 diabetes, autoimmune destruction of β-cells precipitates absolute insulin deficiency. In type 2 diabetes, chronic insulin resistance increases demand on β-cells, which gradually lose mass and secretory competence under glucolipotoxic and inflammatory stress. Genetic predisposition, metabolic overload and cell-intrinsic stress pathways combine to impair glucose sensing, mitochondrial ATP generation and insulin exocytosis. Preserving or restoring functional β-cell mass through immunomodulation, metabolic protection and regenerative approaches remains pivotal to preventing disease progression and complications.

Recent advances in single-cell transcriptomics, live-cell imaging and epigenetic profiling have revealed extensive heterogeneity in β-cell identity, defined by distinct gene expression programmes and dynamic intercellular networks. Studies of mitochondrial bioenergetics and endoplasmic reticulum stress signalling have identified key nodes that regulate survival and secretory capacity under diabetic conditions. Convergence of immunology, developmental biology and regenerative medicine is guiding novel strategies for stem cell–derived β-cell replacement, targeted epigenetic modulation and personalised interventions aimed at re-establishing durable glucose homeostasis on a global scale.

Research from Nature Portfolio

Studies reveal that chronic hyperglycaemia drives a concerted downregulation of oxidative phosphorylation enzymes in diabetic β-cells, leading to reduced NADH and ATP responses to glucose and contributing to secretory failure. Proteomic and transcriptomic analyses in rodent models demonstrate a shift toward glycolytic gene upregulation and compromised mitochondrial metabolism as central mechanisms underlying progressive β-cell dysfunction.

Investigations into human islet architecture have uncovered four antigenically and functionally distinct β-cell subtypes, each exhibiting unique profiles of basal and glucose-stimulated insulin secretion. Notably, subtype distributions are markedly altered in type 2 diabetes, suggesting that selective vulnerability of certain subpopulations contributes to disease pathogenesis and may guide subtype-targeted therapies.

Generation of patient-specific stem cell-derived β-cells from individuals with type 1 diabetes has validated scalable in vitro production of functional insulin-secreting cells that respond to glucose both in vitro and in vivo. These cells mimic native β-cell stress responses without major functional deficits, offering a platform for autologous cell replacement and drug screening.

Research from all publishers

Transient inhibition of the histone methyltransferase EZH2 in exocrine pancreatic cells from type 1 diabetic donors induces epigenetic reprogramming toward a β-like phenotype. Treated cells acquire permissive chromatin marks, express key β-cell genes and demonstrate glucose-regulated insulin secretion ex vivo, highlighting small-molecule epigenetic modulation as a promising regenerative approach.

A comprehensive review has elucidated how excessive mitochondrial reactive oxygen species generation and endoplasmic reticulum stress form a feed-forward loop that exacerbates β-cell dysfunction in type 2 diabetes. This glucolipotoxic environment fosters unresolved inflammation and impairs insulin production, pinpointing oxidative and ER stress pathways as therapeutic targets.

Functional mapping of intact islets has identified specialised β-cell hub populations with pacemaker properties that orchestrate coordinated insulin release. Disruption of these hub cells abolishes network synchrony and reveals their heightened susceptibility to pro-inflammatory and glucolipotoxic insults, suggesting that preserving hub integrity may be critical to maintaining robust secretory responses.

Pancreatic β-Cell Function in Diabetes Pathophysiology publication trend

The graph below shows the total number of articles in pancreatic β-cell function in diabetes pathophysiology across all publications each year (not limited to Nature Index journals).

Technical terms

β-cell: Insulin-producing endocrine cell in the pancreatic islets responsible for regulating blood glucose.

Islets of Langerhans: Clusters of endocrine cells in the pancreas comprising β-cells, α-cells and other hormone-secreting cell types.

Glucolipotoxicity: Cellular injury arising from chronically elevated glucose and lipid levels that impairs β-cell function and viability.

Epigenetic reprogramming: Modulation of gene expression through alterations in chromatin structure, such as DNA methylation or histone modifications, without changing DNA sequence.

Oxidative phosphorylation: Mitochondrial process by which electrons are transferred through respiratory complexes to generate ATP, essential for β-cell insulin secretion.

Endoplasmic reticulum stress: Cellular condition triggered by accumulation of misfolded proteins in the endoplasmic reticulum, activating the unfolded protein response.

References

1. EZH2 inhibitors promote β-like cell regeneration in young and adult type 1 diabetes donors. Signal Transduction and Targeted Therapy (2024).
2. Beta Cell Hubs Dictate Pancreatic Islet Responses to Glucose. Cell Metabolism (2016).
3. Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues. Journal of Clinical Medicine (2019).
4. Human islets contain four distinct subtypes of β cells. Nature Communications (2016).
5. Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nature Communications (2016).
6. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells. Nature Communications (2019).